Kaitlyn Arsenault - 04 Oct 2021 Form 3 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Financial Officer
Signature
Kaitlyn Arsenault
Issuer symbol
SKYE
Transactions as of
04 Oct 2021
Net transactions value
$0
Form type
3
Filing time
05 Oct 2021, 20:40:34 UTC
Next filing
16 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SKYE Stock Option (Right to Buy) 04 Oct 2021 Common Stock 400,000 $0.1200 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 10% of the Options shall vest on September 15, 2021 (the "Vesting Start Date") and the remaining 90% will vest in equal annual installments on the anniversary of the Vesting Start Date over four annual periods.